Intraperitoneal immunotherapy for ovarian cancer with alpha interferon
- 31 May 1992
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 28 (4-5), 719-721
- https://doi.org/10.1016/0959-8049(92)90100-g
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Treatment of malignant ascites due to recurrent/refractory ovarian cancer: the use of interferon-α or interferon-α plus chemotherapy in vivo and in vitroEuropean Journal of Cancer and Clinical Oncology, 1991
- Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cellsGynecologic Oncology, 1990
- A phase I–II trial of intraperitoneal cisplatin and α-lnterferon in patients with persistent epithelial ovarian cancerGynecologic Oncology, 1990
- Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancerEuropean Journal of Cancer and Clinical Oncology, 1990
- Intraperitoneal Lymphokine-Activated Killer Cell/Interleukin-2 Therapy in Patients With Intra- abdominal Cancer: Immunologic ConsiderationsJNCI Journal of the National Cancer Institute, 1989
- A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinomaInvestigational New Drugs, 1988
- Intraperitoneal immunotherapy of epithelial ovarian carcinoma with Corynebacterium parvumAmerican Journal of Obstetrics and Gynecology, 1985
- Cytolytic activity of interferon‐gamma and its synergism with 5‐fluorouracilInternational Journal of Cancer, 1984
- Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assayCancer Chemotherapy and Pharmacology, 1983
- Human leukocyte interferon therapy for advanced ovarian carcinomaAmerican Journal of Clinical Oncology, 1982